These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 24359507)

  • 1. Treatment of cannabis dependence using escitalopram in combination with cognitive-behavior therapy: a double-blind placebo-controlled study.
    Weinstein AM; Miller H; Bluvstein I; Rapoport E; Schreiber S; Bar-Hamburger R; Bloch M
    Am J Drug Alcohol Abuse; 2014 Jan; 40(1):16-22. PubMed ID: 24359507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized double-blind, placebo-controlled trial of venlafaxine-extended release for co-occurring cannabis dependence and depressive disorders.
    Levin FR; Mariani J; Brooks DJ; Pavlicova M; Nunes EV; Agosti V; Bisaga A; Sullivan MA; Carpenter KM
    Addiction; 2013 Jun; 108(6):1084-94. PubMed ID: 23297841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomised Controlled Trial (RCT) of cannabinoid replacement therapy (Nabiximols) for the management of treatment-resistant cannabis dependent patients: a study protocol.
    Bhardwaj AK; Allsop DJ; Copeland J; McGregor IS; Dunlop A; Shanahan M; Bruno R; Phung N; Montebello M; Sadler C; Gugusheff J; Jackson M; Luksza J; Lintzeris N;
    BMC Psychiatry; 2018 May; 18(1):140. PubMed ID: 29776349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial.
    Levin FR; Mariani JJ; Brooks DJ; Pavlicova M; Cheng W; Nunes EV
    Drug Alcohol Depend; 2011 Jul; 116(1-3):142-50. PubMed ID: 21310551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence: A pilot randomized clinical trial.
    Trigo JM; Soliman A; Quilty LC; Fischer B; Rehm J; Selby P; Barnes AJ; Huestis MA; George TP; Streiner DL; Staios G; Le Foll B
    PLoS One; 2018; 13(1):e0190768. PubMed ID: 29385147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacotherapies for cannabis dependence.
    Nielsen S; Gowing L; Sabioni P; Le Foll B
    Cochrane Database Syst Rev; 2019 Jan; 1(1):CD008940. PubMed ID: 30687936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dronabinol and lofexidine for cannabis use disorder: A randomized, double-blind, placebo-controlled trial.
    Levin FR; Mariani JJ; Pavlicova M; Brooks D; Glass A; Mahony A; Nunes EV; Bisaga A; Dakwar E; Carpenter KM; Sullivan MA; Choi JC
    Drug Alcohol Depend; 2016 Feb; 159():53-60. PubMed ID: 26711160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of zolpidem alone and in combination with nabilone on cannabis withdrawal and a laboratory model of relapse in cannabis users.
    Herrmann ES; Cooper ZD; Bedi G; Ramesh D; Reed SC; Comer SD; Foltin RW; Haney M
    Psychopharmacology (Berl); 2016 Jul; 233(13):2469-78. PubMed ID: 27085870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of fixed or self-titrated dosages of Sativex on cannabis withdrawal and cravings.
    Trigo JM; Lagzdins D; Rehm J; Selby P; Gamaleddin I; Fischer B; Barnes AJ; Huestis MA; Le Foll B
    Drug Alcohol Depend; 2016 Apr; 161():298-306. PubMed ID: 26925704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial.
    Allsop DJ; Copeland J; Lintzeris N; Dunlop AJ; Montebello M; Sadler C; Rivas GR; Holland RM; Muhleisen P; Norberg MM; Booth J; McGregor IS
    JAMA Psychiatry; 2014 Mar; 71(3):281-91. PubMed ID: 24430917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacotherapies for cannabis dependence.
    Marshall K; Gowing L; Ali R; Le Foll B
    Cochrane Database Syst Rev; 2014; 12(12):CD008940. PubMed ID: 25515775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: a double-blind, placebo-controlled, parallel group, phase 2a single-site randomised controlled trial.
    D'Souza DC; Cortes-Briones J; Creatura G; Bluez G; Thurnauer H; Deaso E; Bielen K; Surti T; Radhakrishnan R; Gupta A; Gupta S; Cahill J; Sherif MA; Makriyannis A; Morgan PT; Ranganathan M; Skosnik PD
    Lancet Psychiatry; 2019 Jan; 6(1):35-45. PubMed ID: 30528676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma cannabinoid concentrations during dronabinol pharmacotherapy for cannabis dependence.
    Milman G; Bergamaschi MM; Lee D; Mendu DR; Barnes AJ; Vandrey R; Huestis MA
    Ther Drug Monit; 2014 Apr; 36(2):218-24. PubMed ID: 24067260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial.
    Freeman TP; Hindocha C; Baio G; Shaban NDC; Thomas EM; Astbury D; Freeman AM; Lees R; Craft S; Morrison PD; Bloomfield MAP; O'Ryan D; Kinghorn J; Morgan CJA; Mofeez A; Curran HV
    Lancet Psychiatry; 2020 Oct; 7(10):865-874. PubMed ID: 32735782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Marijuana withdrawal in humans: effects of oral THC or divalproex.
    Haney M; Hart CL; Vosburg SK; Nasser J; Bennett A; Zubaran C; Foltin RW
    Neuropsychopharmacology; 2004 Jan; 29(1):158-70. PubMed ID: 14560320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of high-dose dronabinol (oral THC) maintenance on cannabis self-administration.
    Schlienz NJ; Lee DC; Stitzer ML; Vandrey R
    Drug Alcohol Depend; 2018 Jun; 187():254-260. PubMed ID: 29689485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy and tolerability of escitalopram in anxiety disorders: a review].
    Pelissolo A
    Encephale; 2008 Sep; 34(4):400-8. PubMed ID: 18922243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abstinence phenomena of chronic cannabis-addicts prospectively monitored during controlled inpatient detoxification (Part II): Psychiatric complaints and their relation to delta-9-tetrahydrocannabinol and its metabolites in serum.
    Bonnet U; Borda T; Scherbaum N; Specka M
    Drug Alcohol Depend; 2015 Oct; 155():302-6. PubMed ID: 26298553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults.
    Mason BJ; Crean R; Goodell V; Light JM; Quello S; Shadan F; Buffkins K; Kyle M; Adusumalli M; Begovic A; Rao S
    Neuropsychopharmacology; 2012 Jun; 37(7):1689-98. PubMed ID: 22373942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Systematic Review of the Efficacy of Cannabinoid Agonist Replacement Therapy for Cannabis Withdrawal Symptoms.
    Werneck MA; Kortas GT; de Andrade AG; Castaldelli-Maia JM
    CNS Drugs; 2018 Dec; 32(12):1113-1129. PubMed ID: 30361897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.